Medincell and aic unveil new positive phase 3 results for mdc-cwm: major subgroup analysis shows reduced pain and opioid use, and accelerated rehabilitation following total knee replacement

Montpellier, france--(business wire)--analysis of a major subgroup of patients undergoing a first total knee replacement (tkr), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with f14/mdc-cwm (n=51) to those in the control group (n=57)1: 70% reduction in the number of opioid users at 3 months post-surgery, 28% reduction in the total quantity of opioids consumed during the first 3 months post-surgery, lower daily kn.
TKR Ratings Summary
TKR Quant Ranking